CoinScoopKodiak Sciences Shares Surge 170% Following Positive AMD Trial Results
Kodiak Sciences (KOD) shares rose over 170% on Monday after its experimental wet age-related macular degeneration (AMD) treatments, Zenkuda and KSI-501, met primary goals in a Phase 3 study. The company plans to file a Biologics License Application for Zenkuda in the fourth quarter. UBS has issued a Buy rating with an $80 price target, noting the potential for the drugs to offer more convenient dosing compared to current benchmark therapies.
Summaries are written by AI from the original article. Not investment advice.